Clinical Scenario of the Metabolic Syndrome

Visceral Medicine

Volumn 32, Issue 5, 2016, Pages 336-341

  Brede, Swantje ^a   Serfling, Georg ^a   Klement, Johanna ^a   Schmid, Sebastian M ^a   Lehnert, Hendrik ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Abdominal obesity; Cardiovascular disease; Hyperlipidemia; Insulin resistance; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; INSULIN; LEPTIN; LIPID;

ADIPOSE TISSUE; BLOOD CLOTTING; BODY FAT DISTRIBUTION; CANCER RISK; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; HYPERCORTISOLISM; HYPERURICEMIA; LIPID METABOLISM; MALIGNANT NEOPLASM; MENTAL DISEASE; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PRIMARY PREVENTION; REVIEW;

EID: 85015344583     PISSN: 22974725     EISSN: 2297475X     Source Type: Journal    
DOI: 10.1159/000449028     Document Type: Review

References (80)

1. Kesse-Guyot E, Julia C, Andreeva V, Fezeu L, Hercberg S, Galan P: Evidence of a cumulative effect of cardiometabolic disorders at midlife and subsequent cognitive function. Age Ageing 2015; 44: 648-654.
2. Sims EA: Are there persons who are obese, but metabolically healthy? Metabolism 2001; 50: 1499-1504.
3. Despres JP: Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
4. Seidell JC, Han TS, Feskens EJ, Lean ME: Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med 1997; 242: 401-406.
5. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; Interheart Study Investigators: Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
6. Tchernof A, Despres JP: Pathophysiology of human visceral obesity: an update. Physiol Rev 2013; 93: 359- 404.
7. Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM: The hypertriglyceridemic- waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ 2010; 182: 1427-1432.
8. Hayashi T, Boyko EJ, Leonetti DL, McNeely MJ, Newell- Morris L, Kahn SE, Fujimoto WY: Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation 2003; 108: 1718-1723.
9. Poirier P, Lemieux I, Mauriege P, Dewailly E, Blanchet C, Bergeron J, Despres JP: Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 2005; 45: 363-367.
10. Graner M, Siren R, Nyman K, Lundbom J, Hakkarainen A, Pentikainen MO, Lauerma K, Lundbom N, Adiels M, Nieminen MS, Taskinen MR: Cardiac steatosis associates with visceral obesity in nondiabetic obese men. J Clin Endocrinol Metab 2013; 98: 1189-1197.
11. Iacobellis G, Singh N, Wharton S, Sharma AM: Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity (Silver Spring) 2008; 16: 1693-1697.
12. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O'Donnell CJ, Fox CS: Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a communitybased sample: the Framingham Heart Study. Circulation 2008; 117: 605-613.
13. Wong CX, Ganesan AN, Selvanayagam JB: Epicardial fat and atrial fibrillation: current evidence, potential mechanisms, clinical implications, and future directions. Eur Heart J 2016;DOI: 10.1093/eurheartj/ehw045.
14. Ferrante AW Jr: Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 2007; 262: 408-414.
15. van Wijk DF, Boekholdt SM, Arsenault BJ, Ahmadi- Abhari S, Wareham NJ, Stroes ES, Khaw KT: C-reactive protein identifies low-risk metabolically healthy obese persons: the European Prospective Investigation of Cancer-Norfolk Prospective Population study. J Am Heart Assoc 2016; 5:DOI: 10.1161/JAHA.115.002823.
16. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
17. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
18. Dong M, Ren J: What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Curr Pharm Des 2014; 20: 652-658.
19. Lee SW, Jo HH, Kim MR, You YO, Kim JH: Association between metabolic syndrome and serum leptin levels in postmenopausal women. J Obstet Gynaecol 2012; 32: 73-77.
20. Wannamethee SG, Tchernova J, Whincup P, Lowe GD, Rumley A, Brown K, Cherry L, Sattar N: Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) 2007; 31: 1089-1098.
21. El-Haschimi K, Lehnert H: Leptin resistance - or why leptin fails to work in obesity. Exp Clin Endocrinol Diabetes 2003; 111: 2-7.
22. Schulz C, Paulus K, Johren O, Lehnert H: Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (DIO). Endocrinology 2012; 153: 143-153.
23. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K: Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the West Virginian population. Int J Med Sci 2016; 13: 25-38.
24. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I: Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
25. Wang ZV, Scherer PE: Adiponectin, the past two decades. J Mol Cell Biol 2016; 8: 93-100.
26. Yuan G, Qian W, Pan R, Jia J, Jiang D, Yang Q, Wang S, Liu Y, Yu S, Hu H, Sun W, Ye J, Mao C, Zhuang R, Zhou L: Reduced circulating oxytocin and high-molecular- weight adiponectin are risk factors for metabolic syndrome. Endocr J 2016; 63: 655-662.
27. Matsushita K, Tamakoshi K, Yatsuya H, Wada K, Otsuka R, Takefuji S, Hotta Y, Kondo T, Murohara T, Toyoshima H: Further inflammatory information on metabolic syndrome by adiponectin evaluation. Int J Cardiol 2008; 124: 339-344.
28. Kusminski CM, McTernan PG, Schraw T, Kos K, O'Hare JP, Ahima R, Kumar S, Scherer PE: Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 2007; 50: 634-642.
29. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS: Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529.
30. Hayden MR, Tyagi SC: Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation. Nutr J 2004; 3: 4.
31. Catena C, Colussi G, Nait F, Capobianco F, Sechi LA: Elevated homocysteine levels are associated with the metabolic syndrome and cardiovascular events in hypertensive patients. Am J Hypertens 2015; 28: 943-950.
32. Narin F, Atabek ME, Karakukcu M, Narin N, Kurtoglu S, Gumus H, Coksevim B, Erez R: The association of plasma homocysteine levels with serum leptin and apolipoprotein B levels in childhood obesity. Ann Saudi Med 2005; 25: 209-214.
33. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, Selby JV, Saad MF, Savage P, Bergman R: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-1817.
34. Fontes-Carvalho R, Ladeiras-Lopes R, Bettencourt P, Leite-Moreira A, Azevedo A: Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes. Cardiovasc Diabetol 2015; 14: 4.
35. Despres JP: Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 1993; 9: 452-459.
36. Yue JT, Lam TK: Lipid sensing and insulin resistance in the brain. Cell Metab 2012; 15: 646-655.
37. Mulhall BP, Ong JP, Younossi ZM: Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol 2002; 17: 1136-1143.
38. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-1850.
39. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB Jr, Kempf J, Zinman B, Haffner SM; Insulin Resistance Atherosclerosis Study: Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53: 2623-2632.
40. Angulo P, Lindor KD: Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2002; 17(suppl):S186- 190.
41. Sears B, Perry M: The role of fatty acids in insulin resistance. Lipids Health Dis 2015; 14: 121.
42. Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M: Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care 2007; 30: 2916-2921.
43. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994; 91: 10878-10882.
44. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung and Blood Institute: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
45. Tchernof A, Lamarche B, Prud'Homme D, Nadeau A, Moorjani S, Labrie F, Lupien PJ, Despres JP: The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996; 19: 629-637.
46. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF: Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 1999; 103: 1191-1199.
47. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998; 81: 18B-25B.
48. Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiology, effects and treatment. CMAJ 2007; 176: 1113-1120.
49. Verges B: Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis 2010; 211: 353- 360.
50. Rizzo M, Berneis K: Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007; 23: 14-20.
51. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
52. Ungefroren H, Gieseler F, Fliedner S, Lehnert H: Obesity and cancer. Horm Mol Biol Clin Investig 2015; 21: 5-15.
53. Tsugane S, Inoue M: Insulin resistance and cancer: epidemiological evidence. Cancer Sci 2010; 101: 1073- 1079.
54. Strong AL, Strong TA, Rhodes LV, Semon JA, Zhang X, Shi Z, Zhang S, Gimble JM, Burow ME, Bunnell BA: Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res 2013; 15:R102.
55. Ford ES, Li C, Cook S, Choi HK: Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007; 115: 2526- 2532.
56. Bhole V, Choi JW, Kim SW, de Vera M, Choi H: Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010; 123: 957-961.
57. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rhee EJ, Lee WY, Kim SW, Ryu SH, Keum DG: Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933.
58. Krishnan E, Kwoh CK, Schumacher HR, Kuller L: Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007; 49: 298-303.
59. Pacifico L, Cantisani V, Anania C, Bonaiuto E, Martino F, Pascone R, Chiesa C: Serum uric acid and its association with metabolic syndrome and carotid atherosclerosis in obese children. Eur J Endocrinol 2009; 160: 45-52.
60. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
61. Billiet L, Doaty S, Katz JD, Velasquez MT: Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol 2014; 2014: 852954.
62. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S; Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-425.
63. Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP: Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol 2013; 11: 880-905.
64. Faber DR, de Groot PG, Visseren FL: Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10: 554-563.
65. Elbatarny HS, Netherton SJ, Ovens JD, Ferguson AV, Maurice DH: Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007; 558: 7-13.
66. Martinac M, Pehar D, Karlovic D, Babic D, Marcinko D, Jakovljevic M: Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder. Acta Clin Croat 2014; 53: 55-71.
67. Ohaeri JU, Akanji AO: Metabolic syndrome in severe mental disorders. Metab Syndr Relat Disord 2011; 9: 91-98.
68. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-2749.
69. Glueck CJ, Dharashivkar S, Wang P, Zhu B, Gartside PS, Tracy T, Sieve L: Obesity and extreme obesity, manifest by ages 20-24 years, continuing through 32-41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur J Obstet Gynecol Reprod Biol 2005; 122: 206-212.
70. Hart R, Norman R: Polycystic ovarian syndrome - prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol 2006; 20: 751-778.
71. Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H: Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812- 841.
72. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR: The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 2004; 25: 309-340.
73. Pasquali R, Vicennati V, Cacciari M, Pagotto U: The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci 2006; 1083: 111-128.
74. Duclos M, Marquez Pereira P, Barat P, Gatta B, Roger P: Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes Res 2005; 13: 1157-1166.
75. Chiodini I: Clinical review: Diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-1236.
76. Debono M, Prema A, Hughes TJ, Bull M, Ross RJ, Newell-Price J: Visceral fat accumulation and postdexamethasone serum cortisol levels in patients with adrenal incidentaloma. J Clin Endocrinol Metab 2013; 98: 2383-2391.
77. Mitchell BM, Webb RC: Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biol Res Nurs 2002; 4: 16-21.
78. Ivovic M, Marina LV, Vujovic S, Tancic-Gajic M, Stojanovic M, Radonjic NV, Gajic M, Soldatovic I, Micic D: Nondiabetic patients with either subclinical Cushing's or nonfunctional adrenal incidentalomas have lower insulin sensitivity than healthy controls: clinical implications. Metabolism 2013; 62: 786-792.
79. Di Dalmazi G, Vicennati V, Rinaldi E, Morselli-Labate AM, Giampalma E, Mosconi C, Pagotto U, Pasquali R: Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol 2012; 166: 669-677.
80. Dobbins M, Decorby K, Choi BC: The association between obesity and cancer risk: a meta-analysis of observational studies from 1985 to 2011. ISRN Prev Med 2013; 2013: 680536. 363-367